Search Videos by Topic or Participant
Browse by Series:

Selecting a Laboratory for Molecular Testing in NSCLC

Panelists: David R. Gandara, MD, UC Davis; Corey J. Langer, MD, Penn Medicine; Alan B. Sandler, MD, OHSU; Mark A. Socinski, MD, University of Pitt
Published: Monday, Feb 11, 2013
For High-Definition, Click
In this segment, the panelists discuss choosing the most appropriate laboratory for molecular testing. To avoid invalid test results, Alan B. Sandler, MD, recommends a laboratory at an institution that is CLIA certified. Moving forward, he feels there will be less of a need for reference laboratories and more of the testing will be done at larger community centers.

Corey J. Langer, MD, believes that community centers will not be utilized for testing for many more years, due to accuracy concerns. At this time, in the community, Langer notes that test results are generally sent to a central laboratory. However, he points out, even if the results are incredibly accurate they lose some value if they are not ready for 3-5 weeks. On this note, Langer stresses the need for continued dialogue between a community oncologist and their local pathologist.

Mark A. Socinski, MD, and moderator David R. Gandara, MD, touch on the fact that FISH testing for the ALK fusion can be very difficult to perform. In the future, Gandara feels, testing will be done initially with IHC and confirmed using FISH.

In the international community, Anne S. Tsao, MD, points out that many other countries are centralizing their testing. Gandara also adds that in Japan they do not perform FISH testing, all mutations are confirmed using IHC.
Slider Left
Slider Right
For High-Definition, Click
In this segment, the panelists discuss choosing the most appropriate laboratory for molecular testing. To avoid invalid test results, Alan B. Sandler, MD, recommends a laboratory at an institution that is CLIA certified. Moving forward, he feels there will be less of a need for reference laboratories and more of the testing will be done at larger community centers.

Corey J. Langer, MD, believes that community centers will not be utilized for testing for many more years, due to accuracy concerns. At this time, in the community, Langer notes that test results are generally sent to a central laboratory. However, he points out, even if the results are incredibly accurate they lose some value if they are not ready for 3-5 weeks. On this note, Langer stresses the need for continued dialogue between a community oncologist and their local pathologist.

Mark A. Socinski, MD, and moderator David R. Gandara, MD, touch on the fact that FISH testing for the ALK fusion can be very difficult to perform. In the future, Gandara feels, testing will be done initially with IHC and confirmed using FISH.

In the international community, Anne S. Tsao, MD, points out that many other countries are centralizing their testing. Gandara also adds that in Japan they do not perform FISH testing, all mutations are confirmed using IHC.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x